| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| Chemical and physical data | |
| Molar mass | 147 kg/mol |
| | |
Zanolimumab is an investigational human monoclonal antibody and an immunosuppressive drug. It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma. Development of the drug was ultimately discontinued with termination of all trials.
Monoclonal antibodies for the immune system | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Immune system |
| ||||||||||
| Interleukin |
| ||||||||||
| Inflammatory lesions |
| ||||||||||
| |||||||||||